Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Restorative Gel Could Help Reverse Paralysis

By BiotechDaily International staff writers
Posted on 28 May 2013
Print article
A biodegradable implant that delivers a therapeutic gel could help restore healthy nerve function in degenerative disorders such as Parkinson's disease.

Researchers at Tel Aviv University (Israel) developed the implant, which is a soft, biodegradable tube that serves as a physical bridge to help the nerve ends connect. Lining the inside of the biodegradable tube is a guiding regeneration gel (GRG), a transparent, highly viscous, malleable, and adaptable gel that increases nerve growth and healing, helping the severed nerve ends to rejoin. But the GRG not only aids reconnection and cell preservation, it can also support their survival while being used for therapy and transplantation.

The key to the regeneration process lies in the composition of the gel, with three main components: superoxide dismutase (SOD) antioxidants, which exhibit high anti-inflammatory activities; synthetic laminin-derived peptides, which act as a railway or track for the nerve fibers to grow along; and hyaluronic acid, commonly found in the human fetus, which serves as a buffer against drying, a major danger for most implants. These components allow the nerve to heal the way a fetus does in the womb - quickly and smoothly.

Research to-date has shown that GRG stimulates cell growth, neuronal sprouting, and extracellular matrix (ECM) formation, supporting cells in vitro and in vivo upon implantation. It also supports three dimensional (3D) growth and differentiation of various cell types (embryonic, adult stem cells, and preneuronal cells). The implications for therapeutic applications include peripheral nerves reconstruction, cell therapy, corneal preservation, wound healing, and as a postirradiation tissue cavity filler.

“The implant has already been tested in animal models, and the gel by itself can be used as a stand-alone product, acting as an aid to cell therapy,” said GRG codeveloper Shimon Rochkind, MD. “When grown in the gel, cells show excellent development, as well as intensive fiber growth. This could have implications for the treatment of diseases such as Parkinson's.”

Related Links:

Tel Aviv University



Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.